NASDAQ:APLS

Apellis Pharmaceuticals Competitors

$44.48
+2.24 (+5.30 %)
(As of 04/14/2021 04:32 PM ET)
Add
Compare
Today's Range
$42.64
Now: $44.48
$45.15
50-Day Range
$40.80
MA: $44.69
$51.18
52-Week Range
$25.49
Now: $44.48
$58.47
Volume703,847 shs
Average Volume649,188 shs
Market Capitalization$3.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47

Competitors

Apellis Pharmaceuticals (NASDAQ:APLS) Vs. GRFS, TEVA, BHC, RDY, MRVI, and JAZZ

Should you be buying APLS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Apellis Pharmaceuticals, including Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Dr. Reddy's Laboratories (RDY), Maravai LifeSciences (MRVI), and Jazz Pharmaceuticals (JAZZ).

Apellis Pharmaceuticals (NASDAQ:APLS) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Apellis Pharmaceuticals has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Apellis Pharmaceuticals and Grifols, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apellis Pharmaceuticals031012.86
Grifols02502.71

Apellis Pharmaceuticals presently has a consensus price target of $124.6154, suggesting a potential upside of 180.16%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Grifols.

Valuation and Earnings

This table compares Apellis Pharmaceuticals and Grifols' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.59
Grifols$5.71 billion2.15$700.16 million$1.1715.26

Grifols has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Apellis Pharmaceuticals and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apellis PharmaceuticalsN/A-336.93%-78.28%
Grifols12.79%10.65%4.79%

Apellis Pharmaceuticals (NASDAQ:APLS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Apellis Pharmaceuticals and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apellis PharmaceuticalsN/A-336.93%-78.28%
Teva Pharmaceutical Industries-24.17%19.32%4.89%

Insider & Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Apellis Pharmaceuticals and Teva Pharmaceutical Industries, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apellis Pharmaceuticals031012.86
Teva Pharmaceutical Industries19402.21

Apellis Pharmaceuticals presently has a consensus price target of $124.6154, suggesting a potential upside of 180.16%. Teva Pharmaceutical Industries has a consensus price target of $11.80, suggesting a potential upside of 8.46%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Apellis Pharmaceuticals is more favorable than Teva Pharmaceutical Industries.

Valuation & Earnings

This table compares Apellis Pharmaceuticals and Teva Pharmaceutical Industries' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.59
Teva Pharmaceutical Industries$16.89 billion0.70$-998,000,000.00$2.314.71

Apellis Pharmaceuticals has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Apellis Pharmaceuticals has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.

Summary

Apellis Pharmaceuticals beats Teva Pharmaceutical Industries on 8 of the 14 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Apellis Pharmaceuticals and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apellis PharmaceuticalsN/A-336.93%-78.28%
Bausch Health Companies-23.92%173.20%4.21%

Insider & Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Apellis Pharmaceuticals and Bausch Health Companies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apellis Pharmaceuticals031012.86
Bausch Health Companies14702.50

Apellis Pharmaceuticals presently has a consensus price target of $124.6154, suggesting a potential upside of 180.16%. Bausch Health Companies has a consensus price target of $32.5833, suggesting a potential upside of 7.68%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Apellis Pharmaceuticals is more favorable than Bausch Health Companies.

Valuation & Earnings

This table compares Apellis Pharmaceuticals and Bausch Health Companies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.59
Bausch Health Companies$8.60 billion1.25$-1,788,000,000.00$4.436.83

Apellis Pharmaceuticals has higher earnings, but lower revenue than Bausch Health Companies. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Apellis Pharmaceuticals has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Summary

Apellis Pharmaceuticals beats Bausch Health Companies on 7 of the 13 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Volatility and Risk

Dr. Reddy's Laboratories has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Dr. Reddy's Laboratories and Apellis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00403.00
Apellis Pharmaceuticals031012.86

Dr. Reddy's Laboratories currently has a consensus target price of $70.00, suggesting a potential upside of 10.97%. Apellis Pharmaceuticals has a consensus target price of $124.6154, suggesting a potential upside of 180.16%. Given Apellis Pharmaceuticals' higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Earnings & Valuation

This table compares Dr. Reddy's Laboratories and Apellis Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion4.53$259 million$2.7922.61
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.59

Dr. Reddy's Laboratories has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

12.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Dr. Reddy's Laboratories and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Apellis PharmaceuticalsN/A-336.93%-78.28%

Summary

Dr. Reddy's Laboratories beats Apellis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Profitability

This table compares Maravai LifeSciences and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Apellis PharmaceuticalsN/A-336.93%-78.28%

Earnings & Valuation

This table compares Maravai LifeSciences and Apellis Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.59

Analyst Recommendations

This is a summary of recent ratings for Maravai LifeSciences and Apellis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Apellis Pharmaceuticals031012.86

Maravai LifeSciences currently has a consensus target price of $38.1250, suggesting a potential upside of 3.18%. Apellis Pharmaceuticals has a consensus target price of $124.6154, suggesting a potential upside of 180.16%. Given Apellis Pharmaceuticals' higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Maravai LifeSciences.

Insider & Institutional Ownership

81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Apellis Pharmaceuticals beats Maravai LifeSciences on 4 of the 7 factors compared between the two stocks.

Apellis Pharmaceuticals (NASDAQ:APLS) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Profitability

This table compares Apellis Pharmaceuticals and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Apellis PharmaceuticalsN/A-336.93%-78.28%
Jazz Pharmaceuticals7.86%20.16%10.85%

Valuation & Earnings

This table compares Apellis Pharmaceuticals and Jazz Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-9.59
Jazz Pharmaceuticals$2.16 billion4.33$523.37 million$14.6011.40

Jazz Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Apellis Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.

Institutional & Insider Ownership

81.2% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 9.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Apellis Pharmaceuticals and Jazz Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Apellis Pharmaceuticals031012.86
Jazz Pharmaceuticals111602.83

Apellis Pharmaceuticals presently has a consensus price target of $124.6154, suggesting a potential upside of 180.16%. Jazz Pharmaceuticals has a consensus price target of $186.7778, suggesting a potential upside of 12.27%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Apellis Pharmaceuticals is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Apellis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.


Apellis Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Grifols logo
GRFS
Grifols
1.3$17.86+0.1%$12.27 billion$5.71 billion15.95Upcoming Earnings
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.88+1.1%$11.75 billion$16.89 billion-2.96Decrease in Short Interest
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.26+1.5%$10.60 billion$8.60 billion-5.55
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$63.08+0.6%$10.43 billion$2.32 billion52.13News Coverage
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.95+1.5%$9.52 billionN/A0.00Increase in Short Interest
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$166.37+1.8%$9.20 billion$2.16 billion52.48Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.5$202.78+1.7%$8.88 billion$1.45 billion19.18Analyst Report
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.75+2.1%$8.13 billion$40.56 million-16.35Analyst Report
News Coverage
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$161.46+1.0%$8.09 billion$3.34 million-20.97
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$107.97+1.3%$7.14 billion$103.71 million-24.59Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.36+0.2%$6.83 billion$311.33 million-126.95Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$124.24+0.5%$6.71 billion$14.98 million-15.13Analyst Downgrade
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.17+4.8%$6.64 billion$87.99 million-79.96Unusual Options Activity
News Coverage
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.57+0.2%$6.28 billion$150,000.00-21.02
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.83+1.8%$5.79 billion$1.12 billion87.15
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$73.43+4.7%$5.56 billion$380.83 million-9.39
Allakos logo
ALLK
Allakos
1.7$107.59+2.9%$5.55 billionN/A-39.27
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$96.86+3.9%$5.39 billion$66.51 million17.87Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.5$40.38+0.6%$5.36 billion$4.84 billion-672.89
Schrödinger logo
SDGR
Schrödinger
1.3$78.15+3.4%$5.29 billion$85.54 million0.00
Galapagos logo
GLPG
Galapagos
1.3$80.48+2.7%$5.13 billion$1.00 billion-12.19Analyst Report
Gap Down
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$54.58+4.8%$4.73 billionN/A0.00Analyst Report
Increase in Short Interest
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.80+2.7%$4.52 billionN/A-6.10Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.19+1.5%$4.25 billion$204.89 million-36.49
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.67+4.9%$4.20 billion$6.87 million-7.31Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.64+1.8%$4.01 billion$806.43 million-9.58Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47+2.3%$3.88 billion$1.11 billion23.95Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$75.90+1.4%$3.72 billionN/A-21.62Analyst Report
High Trading Volume
News Coverage
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$53.36+2.4%$3.71 billion$117.91 million-10.82
I-Mab logo
IMAB
I-Mab
1.2$55.09+9.9%$3.57 billion$4.31 million-1.91Increase in Short Interest
LEGN
Legend Biotech
1.2$26.76+1.1%$3.49 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.14+2.4%$3.41 billion$114.62 million-7.72Analyst Report
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.90+1.2%$3.33 billion$306.98 million-6.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.28+3.2%$3.30 billion$339.08 million-12.37Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.34+0.3%$3.29 billion$36.13 million-70.66Unusual Options Activity
Insmed logo
INSM
Insmed
1.2$33.02+4.1%$3.27 billion$136.47 million-12.70
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.75+3.7%$3.13 billion$26.52 million-7.91
Alkermes logo
ALKS
Alkermes
1.2$19.23+1.9%$3.00 billion$1.17 billion-41.80
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$115.44+3.8%$3.00 billionN/A-57.43Insider Selling
News Coverage
Arvinas logo
ARVN
Arvinas
1.5$62.89+2.5%$3.00 billion$42.98 million-24.57News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$69.43+1.7%$2.99 billion$421.03 million24.45Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.69+1.5%$2.94 billion$80.43 million108.05Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01+0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.80+0.6%$2.77 billion$644.77 million-10.39
OPKO Health logo
OPK
OPKO Health
1.9$4.20+1.7%$2.77 billion$901.90 million-23.33
Organogenesis logo
ORGO
Organogenesis
1.0$21.90+3.7%$2.70 billion$260.98 million-365.00
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.53+3.4%$2.69 billionN/A-23.92
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.98+6.7%$2.64 billion$182.24 million-8.68Analyst Upgrade
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.95+2.9%$2.61 billion$306.49 million25.79
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.27+3.8%$2.51 billion$60,000.00-10.02
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.